View
213
Download
1
Embed Size (px)
Citation preview
Inpharma 1540 - 3 Jun 2006
Interferon-β-1a and interferon-β-1bhave comparable efficacy in MSInterferon-β-1a and interferon-β-1b appear to have
similar efficacy in the treatment of patients withrelapsing-remitting multiple sclerosis (MS), according tothe results of a multicentre, open-label study.
301 such patients were randomised to receive eitherSC interferon-β-1a 22µg/week (n = 143) or SCinterferon-β-1b 250µg every other day, for 24 months.120 additional patients who declined randomisationreceived the interferon-β-1b regimen.
There was no significant difference in annual relapserate between the randomised interferon-β-1a andinterferon-β-1b groups. However, for interferon-β-1brecipients, the nonrandomised patients had asignificantly higher relapse rate in the first year oftherapy, compared with the randomised patients. Therewas no significant difference in mean time to relapsebetween the randomised interferon-β-1a and interferon-β-1b groups. There was a strong trend towardssignificance in mean time to relapse difference betweenthe nonrandomised patients and the randomisedinterferon-β-1b recipients (361 days vs 431 days;p = 0.07).
The mean time to sustained progression did notsignificantly differ between the two randomisedtreatment groups. However, mean time to progressionwas significantly shorter in the nonrandomisedinterferon-β-1b group, compared with the randomisedinterferon-β-1b recipients (549 days vs 645.6 days).
See also Inpharma 1337 p13; 800888287Koch-Henriksen N, et al. A randomized study of two interferon-beta treatments inrelapsing-remitting multiple sclerosis. Neurology 66: 1056-1060, No. 7, 11 Apr2006 801065181
1
Inpharma 3 Jun 2006 No. 15401173-8324/10/1540-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved